Hansoh Pharmaceutical Group Company (HKG:3692) proprietary antibody-drug conjugate HS-20093 met the primary endpoint in a Phase 3 trial in patients with relapsed or refractory osteosarcoma.
The drug demonstrated a statistically significant improvement in progression-free survival versus chemotherapy, with benefits also seen in overall survival and investigator-assessed progression-free survival, according to a Tuesday Hong Kong bourse filing. The company plans to begin discussions with Chinese regulators to prepare a biologics license application following the positive results.